Alberta Childhood COVID-19 Cohort (AB3C) Aim 3: Longitudinal Sero-Epidemiology Study First Interim Report January 31, 2021
Date
2021-01-31
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The AB3C study has three primary aims:
1. Establish prospective cohort study of all children in Alberta tested for or diagnosed with confirmed or probable COVID-19 infection. (Funded by Alberta Children’s Hospital Research Institute (ACHRI))
2. Conduct a detailed multiomic precision-medicine evaluation of some children in Alberta with confirmed or probable COVID-19 infection, as well as some healthy controls. (Funded by Genome Alberta)
3. Evaluation of the adaptive immune response to SARS-CoV-2 virus in children will be conducted measuring the antibody response against COVID-19 in children with and without clinically apparent confirmed or probable COVID-19 infection in a longitudinal sero-epidemiology study over two years. (Funded by Alberta Health and ACHRI)
The AB3C study has received research ethics and operational approval from the University of Calgary’s and Alberta Health Services’ Conjoint Health Research Ethics Board (CHREB). This report describes the results of the enrolment and first of four visits for Aim 3.
Description
Funded by Government of Alberta and Alberta Children's Hospital Research Institute
Keywords
SARS-CoV-2, COVID-19, immunity, serology, children, pandemic, vaccine